The FDA grants Orphan Drug Designation to treatments for rare diseases in R&D; here are the 10 most recent for oncologic conditions.
The US Food and Drug Administration’s (FDA) Orphan Drug Designation (ODD) denotes medications that are potential promising treatments for rare diseases in their R&D stages.1 Here, we list the 10 most recent ODDs granted to therapies indicated for cancers, with the newest first.2
This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.
Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.
What you’ll discover:
Key trends shaping the pharmaceutical formulation sector
Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
Can’t attend live? No worries – register to receive the recording post-event.
1. ALMB-01683
…the mAb is a first-in-class humanised antibody agonist”
The humanised connexin 43 (Cx43) monoclonal antibody (mAb) received ODD on 18 September. The antibody is produced by AlaMab Therapeutics, Hong Kong and is indicated for osteosarcoma, a type of bone cancer.
According to the company, the mAb is a first-in-class humanised antibody agonist for the hemichannel Cx43 membrane protein. The mechanism of the medication works by activating the Cx43 protein to release cytokines that inhibit tumour growth.
The company behind the drug say that the designation will “allow the group to communicate with the FDA frequently and speed up the clinical development, registration and launch of ALMB-0168.”
2. HCC-specific biomarker4
A drug produced by TCM Biotech International Corporation, Taiwan, to aid in treatment of hepatocellular carcinoma (HCC) was granted ODD on 18 September.
The drug is for use in hepatitis B (HBV)-related HCC as a biomarker for the condition. The marker works using a combination of human and HBC genome to create a particular HBV-human chimera sequence at each infected hepatocyte. An increase of HBV-human chimera DNA in circulation can therefore be used as an HCC-specific biomarker if tumours expand.
According to TCM Biotech, the new platform “could serve as an assistant diagnostic tool to guide the clinicians to determine the intervals of follow-up in high-risk HBV patients or to evaluate residual tumour after curative therapies in HCC patients.”
3. GB12755
The GB1275 medication, produced by GB006 Inc, US, was endorsed with ODD on 11 September. The drug is indicated to treat pancreatic adenocarcinoma.
A current Phase 1 open-label, multicentre trial is studying the treatment as a monotherapy, in combination with an anti-PD1 antibody or in combination with the standard of care. The drug is administered orally twice daily.
The biopharmaceutical company say they are “pursuing product candidates with strong scientific rationale to address indications where there is both a high unmet need and an opportunity to develop best-in-class or first-in-class programmes.”
4. BGJ3986
BGJ398 (infigratinib) is a treatment for cholangiocarcinoma, granted with ODD on 11 September. Produced by QED Therapeutics, US, the drug is an orally administered fibroblast growth factor receptor (FGFR) 1-3 tyrosine kinase inhibitor.
The company say that the mechanism behind the treatment inhibits FGFR4 infrequently, meaning that it is easier for patients to tolerate.
According to the pharma company, their investigative therapy is a first-in-class candidate, as their mission is to focus on precision medicine for FGFR-driven cancers and diseases.
5. PBCAR20A7
A treatment for mantle cell lymphoma received ODD on 11 September, produced by Precision BioSciences Inc, US.
A Phase I/IIa clinical trial is planned for the fourth quarter of 2019 with initial data expected in 2020.
According to the company, PBCAR20A has demonstrated potent in vivo clearance of CD20+ tumour cells and overall tumour volume reduction.
“FDA clearance to begin clinical trials with our anti-CD20 off-the-shelf Chimeric Antigen Receptor (CAR)-T therapy candidate is a significant milestone for Precision… today’s announcement demonstrates our ability to advance multiple product candidates in parallel into the clinic,” commented Matt Kane, CEO and co-founder of the company.
6. GBR 13428
Glenmark Pharmaceuticals, India received ODD for their GBR 1342 treatment for multiple myeloma on 11 September. A first-in-human, open-label, Phase I trial of GBR 1342 is currently ongoing.
The GBR 1342 drug is designed to bind to both CD3 on T cells and CD38, an antigen known to be implicated in haematological malignancies, on target cells. This activates T cells and redirects them toward CD38+ tumour cells found in the condition.
“As one of our first important pipeline milestones, we are excited that the FDA has recognised the potential for GBR 1342 to offer a significant advancement for patients with multiple myeloma,” said Alessandro Riva, MD, CEO of the company.
7. Amg BiTE®9
An Amg BiTE® (bispecific T cell engager) antibody construct with a half-life extension Fc moiety capable of binding to the neonatal Fc receptor, was granted ODD on 11 September. Amgen Inc, US received the designation for the treatment, indicated for acute myeloid leukaemia (AML).
The company say that they are “committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics.”
8. CLS-01410
On 10 September, CLS Therapeutics Inc, US was granted ODD for their CLS-014 (deoxynucleogen) pancreatic cancer treatment.
According to the company, their drug prevents the metastasis of pancreatic adenocarcinoma and is a first-in-class gene therapy platform technology utilising cell-free DNA (cfDNA).
“Receiving ODD marks a major milestone for CLS-014 and an important step forward for our transformative anticancer gene therapy platform… Importantly, we have shown that with our gene therapy approach, we can significantly decrease the primary tumour growth and prevent metastases formation in pancreatic cancer models,” commented Dr George Tetz, MD, co-founder and CEO.
An Investigational New Drug (IND) application is expected to be filed by the business in 2021.
9. IBI-37611
The IBI-376 (parsaclisib) treatment in development from Incyte Corporation, US was endorsed with ODD on 10 September. The drug is to treat splenic marginal zone lymphoma.
…their drug may provide an option… where PI3Kδ has developed resistance”
A phosphatidylinositol 3-kinase delta (Pi3kδ) signal inhibitor, the treatment is targeted at malignant B-cell growth, survival and migration.
According to the company, their primary focus is on oncology. They say their drug may provide an option for patients where PI3Kδ has developed resistance to current treatments.
10. CC-9326912
Celgene International received ODD for their CC-93269 treatment for multiple myeloma on 28 August.
The drug is an asymmetric immunoglobulin G1 (IgG1)-based, B-cell maturation antigen (BCMA) X CD3 T-cell bispecific mAb. It is currently in an open-label, first-in-human Phase I trial.
The company say that their goal is “to deliver truly innovative and life-changing drugs for our patients.”
GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma – Full Text View – ClinicalTrials.gov [Internet]. Clinicaltrials.gov. 2019 [cited 24 September 2019]. Available from: https://clinicaltrials.gov/ct2/show/NCT04060342
Discover Infigratinib | QED Therapeutics | Targeting FGFR [Internet]. QED Therapeutics. 2019 [cited 24 September 2019]. Available from: https://www.qedtx.com/discover-infigratinib/
Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma – Full Text View – ClinicalTrials.gov [Internet]. Clinicaltrials.gov. 2019 [cited 24 September 2019]. Available from: https://clinicaltrials.gov/ct2/show/NCT03486067
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.